Catalog No.
DGK11201
Expression system
Mammalian Cells
Species reactivity
General
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3/chP3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
1E10, CAS: 946832-34-4
Clone ID
Racotumomab
Racotumomab for treating lung cancer and pediatric refractory malignancies, PMID: 26903265
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer, PMID: 24918647
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer, PMID: 25420897
Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy, PMID: 32670370
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients, PMID: 29936534
Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data, PMID: 23110257
Immune response to racotumomab in a child with relapsed neuroblastoma, PMID: 23267436
Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer, PMID: 23162791
A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies, PMID: 26154941
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients, PMID: 24788102
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3, PMID: 23335925
Antibodies to watch in 2015, PMID: 25484055
Cancer vaccine characterization: from bench to clinic, PMID: 24641959
Glycans as targets for therapeutic antitumor antibodies, PMID: 22894669
NGcGM3 ganglioside: a privileged target for cancer vaccines, PMID: 21048926
Which are the antibodies to watch in 2013?, PMID: 23254906
GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy, PMID: 30318083
Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients, PMID: 24777612
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?, PMID: 25148289
Immunotherapy for lung cancer: ongoing clinical trials, PMID: 24143916
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective, PMID: 23112955
Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials, PMID: 27781159
Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model, PMID: 19377876
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody, PMID: 19748674
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism, PMID: 33818952
Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer, PMID: 30318084
For research use only. Not for human or drug use.
